Global Dermatophytic Onychomycosis Market 2016-2020

Global dermatophytic onychomycosis market forecast

Dermatophytic onychomycosis is a fungal infection that is caused by yeast, dermatophytes, and molds, and affects the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. Factors such as the rising prevalence of dermatophytic onychomycosis, heavy investments to develop therapies, and frequent product innovations will aid in the steady growth of the dermatophytic onychomycosis market size during the forecast period. Moreover, the large-scale availability of promising products in the pipeline and the recent rise in diabetic population will result in this market’s steady CAGR of more than 7% by 2020.

An important factor that will impel the prospects for growth in this market is the augmented focus on combination therapies. Recently, it has been observed that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. Since combination therapies have improved clinical efficiency and are more cost-effective than terbinafine, they are increasingly being preferred over individual terbinafine-based therapies as they have a higher cure rate.

Dermatophytic onychomycosis market segmentation by route of administration

• Oral
• Topical

In this market research, analysts have estimated the oral route of drug administration to be more effective when compared to the topical route of drug administration. Medications administered orally ensure a systemic effect as they undergo the first-pass metabolism and are mostly absorbed by the small intestine. Oral drugs include both approved (Lamisil, Sporanox, and Fulvicin) and off-label (Diflucan) drugs.

Geographical segmentation of the dermatophytic onychomycosis market

• Americas
• APAC
• EMEA

In 2015, the Americas dominated this market and is envisaged to retain its dominating market position by the end of 2020 owing to the presence of a well-developed healthcare system. The market in this region is anticipated to reach close to USD 2 billion by 2020.

Competitive landscape and key vendors

The global dermatophytic onychomycosis market is intensely competitive owing to the presence of numerous small and large vendors that operate at a local or global scale. To survive and succeed in this market, the vendors enter into strategic alliances with smaller players to manufacture and market new drugs.

Key vendors in this market are 

• Anacor Pharmaceuticals
• Galderma
• Janssen Biotech
• Novartis
• Valeant Pharmaceuticals

Other prominent vendors in this market are Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma , Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, and Viamet Pharmaceuticals.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global dermatophytic onychomycosis market?
• What are the key market trends impacting the growth of the global dermatophytic onychomycosis market?
• What are the challenges to market growth?
• Who are the key vendors in the global dermatophytic onychomycosis market?
• What are the market opportunities and threats faced by the vendors in the global dermatophytic onychomycosis market?
• What are the trending factors affecting the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global dermatophytic onychomycosis market?

Technavio also offers customization on reports based on specific client requirement.